Immune thrombocytopenic purpura and Guillain-Barré syndrome after 23-valent pneumococcal polysaccharide vaccination in Japan: The Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study.
Immune thrombocytopenic purpura and Guillain-Barré syndrome after 23-valent pneumococcal polysaccharide vaccination in Japan: The Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study.